🇺🇸 FDA
Pipeline program

Triheptanoin

2013-NEUR-001

Phase 2 small_molecule completed

Quick answer

Triheptanoin for Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS) is a Phase 2 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials